BrightPath Biotherapeutics Co., Ltd. reported consolidated earnings results for the year first quarter ended June 30, 2017. For the quarter, on consolidated basis, the company reported net sales of JPY 90 million. Operating loss was JPY 262 million. Ordinary loss was JPY 262 million. Loss attributable to owners of parent was JPY 263 million or loss of JPY 7.08 per share. Loss before income tax was JPY 262.140 million.

For the year ending March 31, 2018, the company expects net sales of JPY 280 million, operating loss of JPY 2,000 million, ordinary loss of JPY 2,000 million and net loss attributable to owners of parent of JPY 2,000 million or JPY 53.73 per share.